Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.13 is 58% above its 3-year average of 0.08, near the low end of its 3-year range (-0.29–4.94).
As of the fiscal period ended Tuesday, June 30, 2026. 24.10% above its 12-month average of 0.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.13.
DEBT TO EQUITY RATIO
0.13
DEBT TO EQUITY RATIO AVG TTM
0.11
DEBT TO EQUITY RATIO AVG 3Y
0.08
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+24.10%
CURRENT VS 3Y AVG
+57.72%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
+2.58%
vs the sector median at left
Maze Therapeutics, Inc.
Market Cap
$1.45B
Debt to Equity Ratio
0.13
TTM Avg
0.11
3Y Avg
0.08
5Y Avg
N/A
Market Cap
$1.46B
Debt to Equity Ratio
0.03
TTM Avg
0.04
3Y Avg
0.07
5Y Avg
0.06
Market Cap
$1.49B
Debt to Equity Ratio
0.62
TTM Avg
1.21
3Y Avg
0.82
5Y Avg
0.68
Market Cap
$1.39B
Debt to Equity Ratio
N/A
TTM Avg
6.73
3Y Avg
5.46
5Y Avg
3.96
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.45B | 0.13 | 0.11 | 0.08 | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.03 | 0.04 | 0.07 | 0.06 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00 | 0.00 | 0.00 | 0.00 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 0.62 | 1.21 | 0.82 | 0.68 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 25.47 | 2.79 | 1.47 | 0.99 |
| Certara, Inc. (CERT)vs › | $1.50B | 0.30 | 0.15 | 0.22 | 0.26 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | 6.73 | 5.46 | 3.96 |
| Innoviva, Inc. (INVA)vs › | $1.53B | 0.22 | 0.44 | 0.63 | 0.69 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.36B | 0.01 | N/A | N/A | N/A |
Debt/Equity
0.13
Current Ratio
18.31
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.13 |
| 2026-03-31 | 0.18 |
| 2025-12-31 | 0.07 |
| 2025-09-30 | 0.06 |
| 2025-06-30 | 0.10 |
| 2025-03-31 | 0.09 |
| 2024-12-31 | 0.14 |
| 2024-09-30 | 0.80 |
| 2024-06-30 | -0.29 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 4.94 |
| 2023-09-30 | 0.00 |
